drugset
drugset / Trial / NCT05359055

Drug-drug Interaction Study of SPH3127

NCT05359055 ↗

Phase 1/2 Completed 40 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in male healthy subjects.

Timeline

Start
2021-12-13
Primary completion
2022-01-21
Completion
2022-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg —
Subject Rifampin Small molecule 600 mg —
Subject sitokiren Small molecule 100 mg —
Subject sitokiren Small molecule 200 mg —

Indications

No indication recorded.